I was at a dinner party in Southeast Portland last weekend where six of the eight people at the table were on GLP-1 drugs. Nobody whispered about it. Nobody was sheepish. Someone mentioned their Mounjaro dose the way you might mention switching to oat milk. Just another lifestyle optimization in the stack.
And I realized: this is not a health trend anymore. This is a consumer behavior earthquake, and every brand strategy deck written before 2024 is operating on outdated assumptions about how people eat, shop, dress, drink, and spend.
This is a consumer behavior earthquake, and every brand strategy deck written before 2024 is operating on outdated assumptions about how people eat, shop, dress, drink, and spend.
Let me count the ways this reshapes brand strategy:
Food brands are in a portion crisis. GLP-1 users eat less. Period. Snack companies, fast casual chains, anyone whose business model depends on volume consumption is watching their per-customer revenue decline. The smart ones are pivoting to premium smaller portions. The slow ones are still running "value size" promotions to an audience that physically cannot eat that much anymore.
Fashion is recalibrating around body flux. When your customer drops three sizes in eight months, their relationship to clothing changes completely. Fast fashion should theoretically benefit (cheap transitional wardrobe), but the data shows GLP-1 users actually trade up. They feel better, they want to look better, they invest more per piece. The opportunity is in elevated basics and capsule wardrobes for bodies in motion.
Alcohol brands are losing occasions. GLP-1 drugs reduce alcohol cravings as a side effect. The non-alcoholic beverage space was already growing. Now it has a pharmacological tailwind. Every spirits brand needs a zero-proof strategy yesterday.
Fitness positioning needs to evolve. The "earn your body through suffering" narrative loses relevance when a weekly injection does most of the work. Fitness brands need to shift from weight loss to performance, mobility, longevity. The why changes even if the what stays the same.
The meta-lesson here is one I keep hammering with clients: your consumer is not static. Their biology is not static. Their relationship to your category is being reshaped by forces outside your category. And if your brand strategy is built on behavioral assumptions you have not pressure-tested in the last twelve months, you are planning for a customer who no longer exists.
The Ozempic economy is not coming. It is here. And it is revealing which brands actually understand their consumer versus which ones just memorized their old habits.